Search the Newsreel

Altimmune to discuss its liver-treatment candidate Aug. 12

Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, including a conference call and webcast at 8:30 a.m. ET to review results and provide a business update. The company is a late clinical-stage biopharmaceutical company developing pemvidutide …

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune, Inc. (Nasdaq: ALT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results and update, which will also be …

AC Immune: Q2 Earnings Snapshot

AC Immune’s Parkinson’s Trial Gets a $4 Million Grant

AC Immune (NASDAQ: ACIU) reported its first-half 2026 financial and corporate update, highlighting a $4 million grant for its Phase 2 VacSYn trial (ACI-7104) for Parkinson’s disease. The company also received a $12 million milestone payment from Takeda for initiating a new cohort in …

Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

The article focuses on the "Price to book forward" metric for Estrella Immunopharma, Inc. (NASDAQ: ESLA), a health technology and biotechnology company. It presents a snapshot of the company's financial overview within the TradingView platform, noting that the market was closed at the time …

Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss

Immuneering (NASDAQ: IMRX) posts Q2 loss while funding MAPKeeper 301 into 2029

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW

Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant …

IMUX Technical Analysis & ETF Price Forecast

The article provides a technical analysis of Immunic, Inc. (IMUX), indicating a "Neutral" sentiment based on various technical indicators. While some moving averages suggest a "Buy" signal given the current share price of $14.05, momentum indicators like RSI and MACD are currently neutral. The …

Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM

Edgestream Partners L.P. has made a new $1.31 million investment in Immunome, Inc. (NASDAQ:IMNM), acquiring 59,888 shares. This investment highlights continued institutional interest, with other hedge funds also adjusting their positions, bringing total institutional ownership to 44.58%. Despite analyst recommendations for a "Moderate Buy" …

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a …

Insider at IMNM (NASDAQ: IMNM) plans sale of 90,616 shares

Alfred K. Horn, an insider at Immunome Inc. (NASDAQ: IMNM), has filed a Form 144 notice to sell up to 90,616 shares of common stock on August 4, 2026, through Fidelity Brokerage Services LLC. This planned sale is in connection with a stock option …

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $2.0243 per share and $5,000 in revenue. Despite a consensus "Moderate Buy" rating and a target price of $43.20, the …

Immunitybio Inc earnings missed by $0.14, revenue topped estimates

Immunitybio Inc (NASDAQ: IBRX) reported second-quarter EPS of $-0.22, missing analyst estimates by $0.14. However, the company's revenue of $51.24M surpassed the consensus estimate of $47.22M. The stock has seen a significant increase of 196.68% over the last 12 months, despite a recent 7.86% …

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

IMVT Maintained by JP Morgan -- Price Target Raised to $50.00

JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The …

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

ImmunityBio (IBRX) reported record second-quarter revenue of $51.2 million, surpassing Wall Street estimates, largely driven by strong sales of its cancer therapy, Anktiva. Despite a wider net loss due to non-cash accounting charges, Chairman Patrick Soon-Shiong highlighted the company's focus on expanding Anktiva's applications …

ImmunityBio Releases Q2 2026 Financial Results

ImmunityBio, Inc. (IBRX) reported a net loss of $230.4M and a loss per share of $0.22 for Q2 2026, widening from Q2 2025 as the company invests in its immunotherapy platform. Despite increased losses, revenue grew significantly to $51.2M, up 92.0% year-over-year, driven by …

ImmunityBio, Inc. (IBRX) Q2 2026 Earnings

ImmunityBio, Inc. (IBRX) reported its Q2 2026 earnings, with an EPS of -$0.22 against an estimated -$0.08, and revenue of $51M, exceeding the $50M estimate. The company's ANKTIVA revenue saw a 94% year-over-year increase, marking its eighth consecutive quarter of sequential gains. The EPS …

Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M

ImmunityBio, Inc. (IBRX) reported Q2 revenue of $51.2 million, surpassing the FactSet estimate of $49.7 million. This earnings flash indicates stronger-than-expected revenue performance for the biotechnology company in the second quarter.

ImmunityBio Q2 revenue rises 92% to record $50.7 million

ImmunityBio (IBRX) reported a significant increase in Q2 2026 total revenue, reaching $51.2 million, with net product revenue up 92% year-over-year to a record $50.7 million. The company's ANKTIVA product continues to drive growth, marking its eighth consecutive quarter of sequential revenue increase, and …

Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX)

ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, and $94.8 million for the first half of 2026. Despite this revenue growth, the company experienced a higher GAAP net loss of $230.4 million in Q2 and …

Altimmune (ALT) Projected to Release Quarterly Earnings on Tuesday

FDA Sets Jan. 6 Target Date for ImmunityBio's ANKTIVA Review

Altimmune (ALT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALT

This article provides a comprehensive overview of Altimmune's FDA-related activities for its drug pemvidutide, detailing clinical trial updates, regulatory submissions, and designations through 2026. Pemvidutide is being developed for conditions including obesity, MASH (metabolic dysfunction-associated steatohepatitis),

Altimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan

Altimmune, Inc. (ALT) CFO Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026, through the company's 2019 Employee Stock Purchase Plan (ESPP). The shares were purchased at $2.414 each, representing 85% of the closing price on that day, for the …

Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ:IBRX) securities who bought shares prior to January 19, 2026, and continue to hold them. The investigation aims to determine if ImmunityBio and its officers engaged in corporate …

Estrella adds third site to EB103 lymphoma trial

Estrella Immunopharma Inc. has activated Oregon Health & Science University as the third clinical site for its STARLIGHT-1 Phase I/II trial of EB103. The trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion will …

Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash

Altimmune has announced the initiation of its PERFORMA Phase 3 trial for pemvidutide. This trial focuses on evaluating the drug's efficacy in patients diagnosed with MASH (Metabolic Dysfunction-Associated Steatohepatitis). The information was released via Reuters and is available on TradingView.

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 4.9% - Should You Sell?

OMERS ADMINISTRATION Corp Makes New Investment in Immunic, Inc. $IMUX

OMERS ADMINISTRATION Corp recently invested in Immunic, Inc. (NASDAQ:IMUX) by acquiring 168,300 shares valued at approximately $187,000, representing about 1.24% of the company. Despite a recent earnings miss, analysts maintain a "Buy" consensus rating with an average price target of $47.57. Immunic, a biopharmaceutical …

ETFs Investing in Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Stocks

This article lists various ETFs that include Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh stocks in their portfolios. The funds are sorted by market value and provide key financial metrics such as weight, issuer, management style, expense ratio, AUM, price, …

Immunovant (IMVT) Stock Forum and Discussion

This page provides a stock forum and discussion platform for Immunovant (IMVT). It allows investors and interested parties to share insights, opinions, and analysis related to the company's stock performance and future prospects. The forum serves as a community hub for active engagement on …

Immutep (NASDAQ: IMMP) ends lung trial, extends cash runway

Immutep Limited (NASDAQ: IMMP) reported mixed Q4 FY26 results, discontinuing its Phase III TACTI-004 lung cancer trial due to futility but showing positive progress in other programs like INSIGHT-003 and IMP761. The company maintains strong liquidity with A$68.87 million in cash and cash equivalents, …

ImmunityBio (IBRX) Could Be 45% Undervalued On UAE ANKTIVA Approval

ImmunityBio (IBRX) has received marketing authorization for ANKTIVA in the UAE for two cancer indications, expanding its global footprint. Despite a recent share price pullback, the company is considered 45% undervalued, with a fair value of $13 compared to its last close of $7.17. …